4402-83-9

Basic information

• Product Name: METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE
• Synonyms: SALOR-INT L322032-1EA;METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLATE;METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE;BUTTPARK 91\12-14;3-(2,6-Dichlorophenyl)-5-Methyl-4-isoxazolylcarboxylic Acid Methyl Ester
• CAS NO: 4402-83-9
• Molecular Formula: C₁₂H₉Cl₂NO₃
• Molecular Weight: 286.11
• Mol File: 4402-83-9.mol
• Article Data: 10

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 382.4 °C at 760 mmHg
• Flash Point: 185.1 °C
• Appearance: /
• Density: 1.37 g/cm³
• Vapor Pressure: 4.72E-06mmHg at 25°C
• Refractive Index: 1.561
• Solubility: Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE(4402-83-9)
• EPA Substance Registry System: METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE(4402-83-9)

Safety Data

• Hazard Codes: Xi:Irritant
• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S37/39:Wear suitable g
• Hazardous Substances Data: 4402-83-9(Hazardous Substances Data)

Usage

Description

METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE is an organic compound that serves as an intermediate in the synthesis of isoxazolyl penicillin derivatives. It is characterized by its unique molecular structure, which includes a methyl group, a 2,6-dichlorophenyl group, and an isoxazole ring attached to a carboxylate group.
Used in Pharmaceutical Industry:
METHYL 3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOXYLATE is used as a key intermediate in the synthesis of isoxazolyl penicillin derivatives for their development as antibiotics. These penicillin derivatives exhibit broad-spectrum antimicrobial activity and are effective against various bacterial infections, making them valuable in the treatment of a wide range of diseases caused by resistant bacteria.

InChI:InChI=1/C12H9Cl2NO3/c1-6-9(12(16)17-2)11(15-18-6)10-7(13)4-3-5-8(10)14/h3-5H,1-2H3

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 2904-62-3 2,6-dichlorobenzonitrile N-oxide 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 23326-27-4 Methyl 2-butynoate 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 

Downstream Products

• 661452-05-7 prop-2-ynyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-14-4 (1-(2-morpholino-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-caroboxylate 
• 1391026-15-5 (1-benzyl-1H-1,2,3-triazol-4-yl)methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-16-6 (1-(4-(1,3-dioxoisoindolin-2-yl)butyl)-1H-1,2,3-triazol-4-yl)methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-17-7 (1-butyl-1H-1,2,3-triazol-4yl)methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-18-8 (1-allyl-1H-1,2,3-triazol-4-yl)methyl 3-(2,6-dichlorophenyl)-5-methylisoxazole-4 carboxylate 
• 287176-81-2 4-(bromomethyl)-3-(2,6-dichlorophenyl)-5-methylisoxazole 
• 175204-38-3 [3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]methanol 
• 1610688-76-0 (E)-methyl 3-(2,6-dichlorophenyl)-5-(2-(dimethylamino)vinyl)isoxazole-4-carboxylate 
• 1610688-83-9 dimethyl 5,5'-((1E,3Z)-4-(dimethylamino)buta-1,3-diene-1,3-diyl)bis(3-(2,6-dichlorophenyl)isoxazole-4-carboxylate) 
• 4462-55-9 3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolylcarbonyl chloride 

Relevant articles and documents

PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof

The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th

Highly Modular Flow Cell for Electroorganic Synthesis

A highly modular electrochemical flow cell and its application in electroorganic synthesis is reported. This innovative setup facilitates many aspects: an easy adjustment of electrode distance, quick exchange of electrode material, and the possibility to easily switch between a divided or undivided cell. However, the major benefit of the cell is the exact thermal positioning of the electrode material into a Teflon piece. Thereby, the application of expensive and nonmachinable electrode materials like boron-doped diamond or glassy carbon can easily be realized in flow cells. By this geometry, the maximum surface of such valuable electrode materials is exploited. The cell size can compete with classical preparative approaches in terms of performance and productivity. The optimization of reaction parameters and an easy up-scaling to larger flow cells is possible. By using this cell, the starting material can be saved in the development of the electroorganic transformations. To demonstrate the utility of this particular cell, two transformations of important building blocks for the fine chemical and pharmaceutical industry were established including an efficient and simple workup protocol.

Design, Synthesis, and in Vitro Evaluation of Novel 3, 7-Disubstituted Coumarin Derivatives as Potent Anticancer Agents

Twenty-seven 3, 7-disubstituted coumarin derivatives were designed, synthesized, and evaluated in vitro as anticancer agents. Most of the compounds showed moderate-to-potent antiproliferative activity against K562 cells. Compounds 7b and 7d were chosen to evaluate the concentration of 50% growth inhibition (GI50) against SN12C, OVCAR, BxPC-3, KATO-III, T24, SNU-1, WiDr, HeLa, K562, and AGS cell lines. The most potent compound 7d was selected for further cell cycle arrest assay in the AGS cell line. The in vitro data indicated that methylation of benzimidazole moiety at the 3-position of coumarin exhibited significant enhancement of anticancer activity. This study should provide important information for further modification and optimization of coumarin derivatives as anticancer agents.